Piper Sandler analyst Jessica Tassan lowered the firm’s price target on Doximity (DOCS) to $40 from $70 and keeps an Overweight rating on the shares. The firm notes 2026 is off to a slow start on soft Q2/Q3 bookings. Doximity says market growth is decelerating to about 5% and sales cycles are elongating as pharma responds to macro volatility. Near-term outlook is bleak, but Piper continues to believe in the power of the Doximity platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $45 from $55 at Wells Fargo
- Doximity: Rebounding Pharma Momentum, Emerging AI Upside, and Attractive Valuation Support Renewed Growth Buy Thesis
- Doximity upgraded to Neutral from Underweight at JPMorgan
- Buy Rating on Doximity: Near‑Term Timing Headwinds Create an Attractive Entry Point Amid Durable Growth and Margin Strength
- Doximity: Buy Rating Reaffirmed as Attractive Valuation and Emerging AI Growth Offset Near‑Term Macro Headwinds